The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

SAN DIEGO, CA--(Marketwire - Mar 7, 2013) - BioLegend in San Diego, CA, a leading provider of antibodies and reagents for biomedical research, has been granted ISO 9001:2008 certification for ...

The BioLegend Campus Extension started in 2015 with a four-year master plan to privatize a public street and convert the existing 7.5-acre, four-parcel plot into an eight-acre biotechnology campus.

BioLegend can breathe a bit easier. The San Diego biological research products supplier, which had been cramped for space, opened a new and larger headquarters this week. BioLegend has more than 500 ...

PerkinElmer, Inc. PKI recently completed its buyout of BioLegend for a total consideration of approximately $5.25 billion. The latest buyout, which is historically the largest for the company, is ...

Massachusetts life science firm PerkinElmer plans to acquire San Diego antibody company BioLegend for $5.25 billion, according to an announcement from the company on Monday. About $2.2 billion of the ...

SAN DIEGO--(BUSINESS WIRE)--BioLegend, leading provider of world-class biological reagents and tools that enable life science discovery from research to cure, today announced the opening of its new ...

(Reuters) - Medical diagnostic firm PerkinElmer Inc said on Monday it would buy BioLegend, a privately held maker of reagents and antibodies used in medical research, for about $5.25 billion in a cash ...

PerkinElmer Inc. said it is buying BioLegend, which provides life science antibodies and reagents, for $5.25 billion in a combination of cash and stock. PerkinElmer said Monday the transaction is ...

SAN DIEGO--(BUSINESS WIRE)-- BioLegend, Inc., a provider of antibodies and reagents for biomedical research, announced today the release of over fifty Brilliant Violet 421™ antibody conjugates for use ...

PerkinElmer, Inc. PKI recently completed its buyout of BioLegend for a total consideration of approximately $5.25 billion. The latest buyout, which is historically the largest for the company, is ...

Medical diagnostic firm PerkinElmer Inc said on Monday it would buy BioLegend, a privately held maker of reagents and antibodies used in medical research, for about $5.25 billion in a cash-and-stock ...